$OTLK Up 35% Premarket 🚀 🔹 Outlook Therapeutics ripping after winning its FDA appeal for ONS-5010 / LYTENAVA 📈 🔹 FDA granted the appeal following the Formal

$OTLK Up 35% Premarket 🚀 🔹 Outlook Therapeutics ripping after winning its FDA appeal for ONS-5010 / LYTENAVA 📈 🔹 FDA granted the appeal following the Formal Dispute Resolution process — a major regulatory reset for the wet AMD program 👁️ 🔹 LYTENAVA is already authorized in the EU & UK, with U.…